Vitrolife AB · OMXSTO:VITR

Vitrolife AB — Q1 2020 Earnings Presentation

9 slides from Vitrolife AB's earnings presentation, Apr 23, 2020

  1. Slide 1: Vitrolife AB (publ) Interim report January - March 2020

    VITROLIFE AB (PUBL) Interim report January - March 2020 2020-04-23 Thomas Axelsson, CEO Mikael Engblom, CFO 1

  2. Slide 2: Good growth but uncertain second quarter

    GOOD GROWTH BUT UNCERTAIN SECOND QUARTER Q1:  Sales of 334 MSEK (312) equals +7% in SEK.  Sales increased by 5% in local currency and consisted of organic growth.  EBITDA of 116 MSEK (126) corresponding to a margin of 35% (40). After the end of the period:  Large reduction in inflow of orders du

  3. Slide 3: Sales and growth per market region

    SALES AND GROWTH PER MARKET REGION SHARE OF VITROLIFE’S SALES 19% 41% 23% 17% ROLLING 12-MONTHS Q1 GROWTH RATE COMPARED TO LAST YEAR IN LOCAL CURRENCIES +7% +17% -22% +14% Total +5%* 3 * Whereof organic growth +5 percent

  4. Slide 4: Sales and growth per division

    SALES AND GROWTH PER DIVISION SEK millions, rolling 12m 1600 1400 125 136 GENOMICS +52% 91 1200 54 20 398 442 488 506 TECHNOLOGY +19% 1000 352 342 355 351 332 800 600 400 695 711 737 772 802 820 834 842 835 CONSUMABLES -5% 200 0 Quarterly growth, Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 local currency 2018 2019 2

  5. Slide 5: Current situation and short-term outlook

    CURRENT SITUATION AND SHORT-TERM OUTLOOK  After closing day, the negative sales trend from the end of the first quarter accelerated.  Sales during the first weeks of April amounted to approximately a third of the previous year.  Demand reduced due to introduced restrictions, recommendations (ESHR

  6. Slide 6: Key financials Group Q1

    KEY FINANCIALS GROUP Q1 • Fluctuations in exchange rates positively impacted EBITDA by 10 MSEK. • EBITDA margin negatively impacted by covid-19 (sales, product mix and obsolescence costs). • Cash and cash equivalents at the end of the period amounted to 715 MSEK. No financial loans. 2020 2019 2019 2

  7. Slide 7: Long-term outlook

    LONG-TERM OUTLOOK  Long-term market growth 5-10% in monetary terms  Expansion of sales  Broadening the product offering 7

  8. Slide 8: Contact

    Contact: Thomas Axelsson, CEO, taxelsson@vitrolife.com, +46 31 721 80 01 Mikael Engblom, CFO, mengblom@vitrolife.com, +46 31 721 80 14

  9. Slide 9: Disclaimer

    DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i

Vitrolife — Q1 2020 Earnings Presentation on 6ix